Clinical Trial Update: IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating IL13Rα2 CAR-T cells that secrete anti-PD-L1 antibody for recurrent malignant glioma; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• IL13Rα2 CAR-T Cells secreting anti-PD-L1 antibody

Snippet

Sponsor: Ming Yang | Conditions: Recurrent Malignant Glioma | Phase 1 | Status: NOT_YET_RECRUITING